184 related articles for article (PubMed ID: 25720750)
21. Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma.
Adams HJ; Kwee TC
Eur J Haematol; 2016 Dec; 97(6):491-498. PubMed ID: 27528557
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi.
Rigacci L; Vitolo U; Nassi L; Merli F; Gallamini A; Pregno P; Alvarez I; Salvi F; Sancetta R; Castagnoli A; Versari A; Biggi A; Gregianin M; Pelosi E; Chisesi T; Bosi A; Levis A;
Ann Hematol; 2007 Dec; 86(12):897-903. PubMed ID: 17701410
[TBL] [Abstract][Full Text] [Related]
23. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
25. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
26. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
28. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results.
Molnar Z; Simon Z; Borbenyi Z; Deak B; Galuska L; Keresztes K; Miltenyi Z; Marton I; Rosta A; Schneider T; Tron L; Varady E; Illes A
Neoplasma; 2010; 57(4):349-54. PubMed ID: 20429626
[TBL] [Abstract][Full Text] [Related]
30. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma.
Oki Y; Chuang H; Chasen B; Jessop A; Pan T; Fanale M; Dabaja B; Fowler N; Romaguera J; Fayad L; Hagemeister F; Rodriguez MA; Neelapu S; Samaniego F; Kwak L; Younes A
Br J Haematol; 2014 Apr; 165(1):112-6. PubMed ID: 24386943
[TBL] [Abstract][Full Text] [Related]
32. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
33. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of 18F-FDG PET-CT in Hodgkin lymphoma].
Ying Z; Wang X; Song Y; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Liu W; Deng L; Zhang C; Yang Z; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):325-7. PubMed ID: 24759021
[TBL] [Abstract][Full Text] [Related]
35. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results].
Molnár Z; Simon Z; Borbényi Z; Deák B; Galuska L; Keresztes K; Miltényi Z; Marton I; Rosta A; Schneider T; Trón L; Várady E; Illés A
Orv Hetil; 2009 Nov; 150(47):2133-8. PubMed ID: 19910278
[TBL] [Abstract][Full Text] [Related]
37. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
Romano A; Parrinello NL; Vetro C; Forte S; Chiarenza A; Figuera A; Motta G; Palumbo GA; Ippolito M; Consoli U; Di Raimondo F
Br J Haematol; 2015 Mar; 168(5):689-700. PubMed ID: 25376846
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
39. The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials.
Angelopoulou MK; Mosa E; Pangalis GA; Rondogianni P; Chatziioannou S; Prassopoulos V; Moschogianni M; Tsirkinidis P; Asimakopoulos JV; Konstantinou I; Tsourouflis G; Sachanas S; Yiakoumis X; Boutsikas G; Arapaki M; Gainaru G; Kyrtsonis MC; Siakantaris MP; Datseris I; Panayiotidis P; Konstantopoulos K; Vassilakopoulos TP
Anticancer Res; 2017 Oct; 37(10):5727-5736. PubMed ID: 28982893
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
